Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.48 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | IAPP | P10997 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852860 | 1.00 | AKR1B1 (0.55) | AKR1B1MTNR1AMTNR1BHSPA5L3MBTL1 | |
| SCHEMBL6514070 | 0.92 | AKR1B1 (0.47) | AKR1B1MTNR1AMTNR1BHSPA5L3MBTL1 | |
| SCHEMBL9863289 | 0.89 | MTNR1A (0.52) | MTNR1AMTNR1BL3MBTL1CYP2C19HIF1A | |
| SCHEMBL2821947 | 0.83 | CYP4F2 (0.47) | AKR1B1HSPA5IAPP | |
| SCHEMBL12318344 | 0.82 | MTNR1A (0.48) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL23241571 | 0.81 | MTNR1A (0.51) | MTNR1AMTNR1BL3MBTL1IDO1CYP2C19 | |
| SCHEMBL16940009 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL19994734 | 0.81 | MTNR1A (0.51) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL22532318 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL4671563 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BL3MBTL1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022047008-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| CN-105555766-A | Aminomethyl-biaryl derivatives as complement factor D inhibitors and uses thereof | NOVARTIS AG | 2016-05-04 | — | — | CN | disclosed |
| US-20150241779-A1 | REAGENT FOR ENHANCING GENERATION OF CHEMICAL SPECIES | OSAKA UNIVERSITY (JP) | 2015-08-27 | — | — | US | disclosed |
| WO-2015125495-A1 | Reagent for Enhancing Generation of Chemical Species | TOYO GOSEI CO., LTD. (JP) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-6974658-B2 | HIGH MOLECULAR COMPOUND, MONOMER COMPOUNDS AND PHOTOSENSITIVE COMPOSITION FOR PHOTORESIST, PATTERN FORMING METHOD UTILIZING PHOTOSENSITIVE COMPOSITION, AND METHOD OF MANUFACTURING ELECTRONIC COMPONENTS | KABUSHIKI KAISHA TOSHIBA (JP) | 2005-12-13 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| US-6413679-B1 | HERMETIC SEALED CONTAINER | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | AKR1B1 2141/4885MTNR1A 1965/4885MTNR1B 1168/4885 |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | AKR1B1 1456/4885MTNR1A 3981/4885MTNR1B 2745/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | AKR1B1 1769/4885MTNR1A 3930/4885MTNR1B 3580/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | AKR1B1 1319/4885MTNR1A 3848/4885MTNR1B 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.